Jazz Pharmaceuticals

Jazz Pharmaceuticals

JAZZ· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock +38.0% in FY2025

Renee D. Gala is the CEO of Jazz Pharmaceuticals and was paid $19.2M in FY2025 (Dec), up 189%.

Pay$100 in the stock at the end of FY22 → $107
CEO pay is from each Jazz Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives6

See all
  1. 1Renee D. GalaFY2025
  2. 2Bruce C. CozaddFY2025
  3. 3Philip L. JohnsonFY2025
  4. 4Neena M. PatilFY2025
  5. 5Samantha PearceFY2025
  6. 6Robert Iannone, M.D., M.S.C.EFY2024

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Jazz Pharmaceuticals paid its 5 named executives $57.9M in total in FY2025 (Dec). CEO Renee D. Gala was paid $19.2M of that.

Name
Renee D. GalaPresident, CEO and Director
Bruce C. CozaddChairperson and former CEO
Philip L. JohnsonExecutive Vice President and CFONot disclosed
Neena M. PatilExecutive Vice President and Chief Legal Officer
Samantha PearceExecutive Vice President, Chief Commercial OfficerNot disclosed
Robert Iannone, M.D., M.S.C.EExecutive Vice President, Global Head of R&DNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers13

See all

The FY2025 (Dec) proxy of Jazz Pharmaceuticals names 13 peer companies for pay. Pay versus performance data of Jazz Pharmaceuticals for that year is not on file, so it has no rank.

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board4

See all
  • Bruce C. CozaddChair · 22 yr on the boardNot independent—Paid as an executive
  • Patrick EnrightDirector · 16 yr on the boardNot independentAudit, Compensation—Paid as an executive
  • Mark D. Smith, M.D.Director · 5 yr on the boardNot independentNominating, Science and Medicine—Paid as an executive
  • Renee D. GalaDirector · 0 yr on the boardNot independent—Paid as an executive

The board of the latest proxy (FY2025).

Activity

  1. Pay
    Jazz Pharmaceuticals Division head pay rose 36% to $6.1M. The stock rose 38% in FY2025 (Dec).
    DEF 14A
  2. Pay
    Jazz Pharmaceuticals CEO pay rose 189% to $19.2M. The stock rose 38% in FY2025 (Dec).
    DEF 14A
  3. Pay
    Jazz Pharmaceuticals CEO pay rose 22% to $6.6M. The stock did not change in FY2024 (Dec).
    DEF 14A
  4. Pay
    Jazz Pharmaceuticals CFO pay rose 44% to $7.5M. The stock rose 38% in FY2025 (Dec).
    DEF 14A
  5. Pay
    Jazz Pharmaceuticals General counsel pay rose 46% to $6.3M. The stock rose 38% in FY2025 (Dec).
    DEF 14A
  6. Pay
    Jazz Pharmaceuticals General counsel pay rose 11% to $4.3M. The stock did not change in FY2024 (Dec).
    DEF 14A
  7. Pay
    Jazz Pharmaceuticals Chair pay rose 21% to $18.8M. The stock rose 38% in FY2025 (Dec).
    DEF 14A
  8. Board
    Renee D. Gala joined the board of Jazz Pharmaceuticals. Renee D. Gala now sits on 2 public boards.
    3
  9. Pay
    Jazz Pharmaceuticals Division head pay rose 14% to $5.7M. The stock did not change in FY2024 (Dec).
    DEF 14A
  10. Pay
    Jazz Pharmaceuticals COO pay rose 22% to $6.6M. The stock did not change in FY2024 (Dec).
    DEF 14A
  11. Pay
    Jazz Pharmaceuticals Division head pay rose 21% to $4.9M. The stock rose 25% in FY2022 (Dec).
    DEF 14A
  12. Pay
    Jazz Pharmaceuticals President pay rose 10% to $6.0M. The stock rose 25% in FY2022 (Dec).
    DEF 14A
  13. Pay
    Jazz Pharmaceuticals Chair pay fell 11% to $15.3M. The stock fell 23% in FY2023 (Dec).
    DEF 14A
  14. Pay
    Jazz Pharmaceuticals Chair pay rose 10% to $17.3M. The stock rose 25% in FY2022 (Dec).
    DEF 14A
  15. Board
    Patrick Kennedy joined the board of Jazz Pharmaceuticals. Patrick Kennedy sits on no other public board.
    3

Filings6

See all
Proxy statementDEF 14AJun 8, 2026FY2025
Annual report10-KFeb 24, 2026FY2025
Proxy statementDEF 14AJun 6, 2025FY2024
Annual report10-KFeb 26, 2025FY2024
Proxy statementDEF 14AJun 14, 2024FY2023
Annual report10-KFeb 28, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data